Premium
Abnormalities of the contrast re‐circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast‐enhanced imaging: A possible marker of vascular tortuosity
Author(s) -
Kassner A.,
Annesley D.J.,
Zhu X.P.,
Li K.L.,
KamalyAsl I.D.,
Watson Y.,
Jackson A.
Publication year - 2000
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/(sici)1522-2586(200002)11:2<103::aid-jmri5>3.0.co;2-z
Subject(s) - magnetic resonance imaging , contrast (vision) , dynamic contrast , dynamic contrast enhanced mri , pathology , medicine , abnormality , cerebral blood volume , phase contrast microscopy , nuclear magnetic resonance , radiology , computer science , physics , artificial intelligence , psychiatry , optics
Dynamic susceptibility contrast‐enhanced magnetic resonance (MR) imaging in tumors is restricted by relaxivity effects, which may obscure any abnormality of first‐pass kinetics in the re‐circulation phase. The purposes of this study were a) to document the magnitude of relaxivity effects with a variety of commonly used MR susceptibility imaging techniques; and b) to determine whether the re‐circulation phase of the first‐pass curve in tumors differs from that in normal tissue. We have confirmed that residual relaxivity effects can be eliminated from dynamic susceptibility contrast‐enhanced data by several techniques. Application of these methods to enhancing vascular tumors allows detection of abnormalities in the re‐circulation phase, which would otherwise be obscured. These abnormalities are independent of relative cerebral blood volume (rCBV) and presumably represent deviations from the predicted gamma variat flow pattern seen in normal tissues. We believe that the parameter rR described here provides an indicator of the chaotic nature of neovascular angiogenesis, which may be of benefit in diagnosis and management. J. Magn. Reson. Imaging 2000;11:103–113. © 2000 Wiley‐Liss, Inc.